Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel

Leukemia and Lymphoma

Volumn 50, Issue 4, 2009, Pages 670-672

  Yamazaki, Rie ^a,b   Aisa, Yoshinobu ^a   Mori, Takehiko ^a   Iketani, Osamu ^c   Ikeda, Yasuo ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; HYDROXYUREA; IMATINIB;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COLON RESECTION; CROHN DISEASE; CYTOGENETICS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; ILEOSTOMY; MALE; NAUSEA; PRIORITY JOURNAL; PROCTOCOLECTOMY; SHORT BOWEL SYNDROME; SINGLE DRUG DOSE; STOMA; TREATMENT RESPONSE;

ADULT; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL ABSORPTION; INTESTINES; JEJUNUM; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 68449102447     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902777459     Document Type: Article

References (11)

1. Drucker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
2. Savage DG, Antman KH. Drug therapy: Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002; 346:683-693.
3. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, et al. Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-162.
4. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002;768:325-340.
5. Peng B, Hayes M, Resta D, Racine-Poon A, Drucker BJ, Talpez M, et al. Pharmacokinetics and pharmacodynamics of Imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-942.
6. Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III study. Br J Clin Pharmacol 2004;60:35-44.
7. Larson RA, Druker BJ, Guilhot FA, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 2008;111: 4022-4028.
8. Beumer JH, Natale JJ, Lagattuta TF, Raptis A, Eqorin MJ. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 2006;26:903-907.
9. Deininger MW, O'Brien SG, Ford JM, Drucker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21: 1637-1647.
10. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical Cancer Res 2002;8:935-942.
11. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/ or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Res 2002;8: 3034-3038.